$ATYR Income Statement | Understand Stock

$ATYR

$0.12 -$0.03 (20.34%) Live

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
License and collaboration agreement revenues
Total revenues

Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Total other income (expense), net
Consolidated net loss
Net loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited
Net loss attributable to aTyr Pharma, Inc.
Net loss per share, basic and diluted
Shares used in computing net loss per share, basic and diluted
Net loss per share - basic
Net loss per share - diluted
Shares used in computing net loss per share, basic
Shares used in computing net loss per share, diluted

Comments